{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:55:45Z","timestamp":1793778945293,"version":"4.6.1"},"reference-count":59,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Quality of life impairment in dermatology patients and severity of psoriasis are quantified by the Dermatology Life Quality Index (DLQI) and the Psoriasis Area and Severity Index (PASI), respectively. The aim of this study is to compare the correlation between PASI and DLQI in patients from different geographical areas and to identify predictors of high DLQI across geographical regions. Correlations between PASI and DLQI were evaluated using Spearman\u2019s rank correlation tests and quantile regression. The study included 1,158 patients with psoriasis, with a median (interquartile range) PASI and DLQI of 6.0 (3.0\u201312.0) and 8.0 (4.0\u201315.0), respectively. Correlations were demonstrated between PASI and DLQI, both overall and stratified by geographical region. Quantile (median) regression yielded coefficients of 0.75 (95% confidence interval (95% CI) 0.62, 0.88) for Switzerland, 0.50 (95% CI 0.42, 0.58) for Latin America, 0.34 (95% CI 0.16, 0.51) for Asia, and 0.31 (95% CI 0.08, 0.53) for the USA. Current age, age at diagnosis, sex, body mass index, and psoriasis arthritis affected DLQI in Latin America, while education had an impact among patients treated in Switzerland. Few countries were included within each continent; hence, more data from different countries are necessary for generalizability. The study showed correlations between PASI and DLQI among patients in all included geographical regions. The patients\u2019 characteristics affecting DLQI vary worldwide.<\/jats:p>","DOI":"10.2340\/actadv.v104.20329","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T12:17:15Z","timestamp":1710245835000},"page":"adv20329","source":"Crossref","is-referenced-by-count":28,"title":["Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis"],"prefix":"10.2340","volume":"104","author":[{"given":"Julia-Tatjana","family":"Maul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara W.","family":"Maul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes A.","family":"Didaskalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Romiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Korouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Novoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazel H.","family":"Oon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jashin J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia-Louise","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"51344","doi-asserted-by":"crossref","unstructured":"Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-385.","DOI":"10.1038\/jid.2012.339"},{"key":"51345","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/jid.2012.339","DOI":"10.1038\/jid.2012.339"},{"key":"51346","doi-asserted-by":"crossref","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 2020; 369: m1590-m1590.","DOI":"10.1136\/bmj.m1590"},{"key":"51347","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmj.m1590","DOI":"10.1136\/bmj.m1590"},{"key":"51348","doi-asserted-by":"crossref","unstructured":"Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 2019; 80: 251-265.e19.","DOI":"10.1016\/j.jaad.2018.06.027"},{"key":"51349","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2018.06.027","DOI":"10.1016\/j.jaad.2018.06.027"},{"key":"51350","doi-asserted-by":"crossref","unstructured":"Iskandar IYK, Ashcroft DM, Warren RB, Yiu ZZN, McElhone K, Lunt M, et al. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. Br J Dermatol 2015; 173: 510-518.","DOI":"10.1111\/bjd.13908"},{"key":"51351","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.13908","DOI":"10.1111\/bjd.13908"},{"key":"51352","doi-asserted-by":"crossref","unstructured":"Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741.","DOI":"10.1001\/jama.296.14.1735"},{"key":"51353","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jama.296.14.1735","DOI":"10.1001\/jama.296.14.1735"},{"key":"51354","doi-asserted-by":"crossref","unstructured":"Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407.","DOI":"10.1016\/S0190-9622(99)70112-X"},{"key":"51355","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0190-9622(99)70112-X","DOI":"10.1016\/S0190-9622(99)70112-X"},{"key":"51356","doi-asserted-by":"crossref","unstructured":"Maul J-T, Navarini AA, Sommer R, Anzengruber F, Sorbe C, Mrowietz U, et al. Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice. J Eur Acad Dermatol Venereol 2019; 33: 700-708.","DOI":"10.1111\/jdv.15324"},{"key":"51357","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.15324","DOI":"10.1111\/jdv.15324"},{"key":"51358","doi-asserted-by":"crossref","unstructured":"Maul J-T, Augustin M, Sorbe C, Conrad C, Anzengruber F, Mrowietz U, et al. Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study. Br J Dermatol 2021; 185: 1160-1168.","DOI":"10.1111\/bjd.20387"},{"key":"51359","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.20387","DOI":"10.1111\/bjd.20387"},{"key":"51360","doi-asserted-by":"crossref","unstructured":"Blome C, Gosau R, Radtke MA, Reich K, Rustenbach SJ, Spehr C, et al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res 2016; 308: 69-78.","DOI":"10.1007\/s00403-015-1613-8"},{"key":"51361","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00403-015-1613-8","DOI":"10.1007\/s00403-015-1613-8"},{"key":"51362","doi-asserted-by":"crossref","unstructured":"de Ruiter CC, Rustemeyer T. Biologics can significantly improve Dermatology Life Quality Index (DLQI) in psoriatic patients: a systematic review. Psoriasis (Auckland, NZ). 2022; 12: 99-112.","DOI":"10.2147\/PTT.S356568"},{"key":"51363","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/PTT.S356568","DOI":"10.2147\/PTT.S356568"},{"key":"51364","doi-asserted-by":"crossref","unstructured":"Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Cs\u00f6rg\u00f6 Z, Boonen H, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol 2020; 34: 2461-2498.","DOI":"10.1111\/jdv.16915"},{"key":"51365","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.16915","DOI":"10.1111\/jdv.16915"},{"key":"51366","doi-asserted-by":"crossref","unstructured":"Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Cs\u00f6rg\u00f6 Z, Boonen H, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 2021; 35: 281-317.","DOI":"10.1111\/jdv.16926"},{"key":"51367","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.16926","DOI":"10.1111\/jdv.16926"},{"key":"51368","doi-asserted-by":"crossref","unstructured":"Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol 2020; 82: 117-122.","DOI":"10.1016\/j.jaad.2019.08.026"},{"key":"51369","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2019.08.026","DOI":"10.1016\/j.jaad.2019.08.026"},{"key":"51370","doi-asserted-by":"crossref","unstructured":"Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol 2014; 28: 333-337.","DOI":"10.1111\/jdv.12106"},{"key":"51371","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.12106","DOI":"10.1111\/jdv.12106"},{"key":"51372","doi-asserted-by":"crossref","unstructured":"Valenzuela F, De La Cruz C, Lecaros C, Fern\u00e1ndez J, Hevia G, Maul LV, et al. Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis. Clin Exp Dermatol 2022; 47: 2234-2241.","DOI":"10.1111\/ced.15384"},{"key":"51373","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ced.15384","DOI":"10.1111\/ced.15384"},{"key":"51374","doi-asserted-by":"crossref","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"51375","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"51376","doi-asserted-by":"crossref","unstructured":"Norris D, Photiou L, Tacey M, Dolianitis C, Varigos G, Foley P, et al. Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population. J Dermatolog Treat 2017; 28: 731-736.","DOI":"10.1080\/09546634.2017.1329501"},{"key":"51377","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2017.1329501","DOI":"10.1080\/09546634.2017.1329501"},{"key":"51378","doi-asserted-by":"crossref","unstructured":"Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2017; 31: 213-220.","DOI":"10.1111\/jdv.14007"},{"key":"51379","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.14007","DOI":"10.1111\/jdv.14007"},{"key":"51380","doi-asserted-by":"crossref","unstructured":"Muslimani MA, Bolcato V, de Silvestri A, Brazzelli V. Psoriatic patients undergoing long-term therapy with biologics: impact of residual localization of psoriasis on quality of life in an Italian clinical setting. Dermatol Ther 2020; 33: e14337.","DOI":"10.1111\/dth.14337"},{"key":"51381","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.14337","DOI":"10.1111\/dth.14337"},{"key":"51382","doi-asserted-by":"crossref","unstructured":"Houghton K, Patil D, Gomez B, Feldman SR. Correlation between change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in patients with psoriasis: pooled analysis from four phase 3 clinical trials of secukinumab. Dermatol Ther (Heidelb) 2021; 11: 1373-1384.","DOI":"10.1007\/s13555-021-00564-2"},{"key":"51383","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s13555-021-00564-2","DOI":"10.1007\/s13555-021-00564-2"},{"key":"51384","doi-asserted-by":"crossref","unstructured":"Maul J-T, Fr\u00f6hlich F, Maul LV, Stunnenberg R, Valenzuela F, De La Cruz C, et al. Access to psoriasis treatment in Brazil and Chile: a cross-sectional multicentre Global Healthcare Study on Psoriasis. Br J Dermatol 2023; 188: 533-441.","DOI":"10.1093\/bjd\/ljac128"},{"key":"51385","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/bjd\/ljac128","DOI":"10.1093\/bjd\/ljac128"},{"key":"51386","unstructured":"Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, et al. SciPy 1.0-Fundamental Algorithms for Scientific Computing in Python. CoRR 2019; abs\/1907.1. Available from: http:\/\/arxiv.org\/abs\/1907.10121"},{"key":"51387","doi-asserted-by":"crossref","unstructured":"Seabold S, Perktold J. statsmodels: Econometric and statistical modeling with python. In: 9th Python in Science Conference. 2010.","DOI":"10.25080\/Majora-92bf1922-011"},{"key":"51388","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.25080\/Majora-92bf1922-011","DOI":"10.25080\/Majora-92bf1922-011"},{"key":"51389","doi-asserted-by":"crossref","unstructured":"Hunter JD. Matplotlib: A 2D Graphics Environment. Comput Sci Eng 2007; 9: 90-95.","DOI":"10.1109\/MCSE.2007.55"},{"key":"51390","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1109\/MCSE.2007.55","DOI":"10.1109\/MCSE.2007.55"},{"key":"51391","doi-asserted-by":"crossref","unstructured":"Damiani G, Bragazzi NL, Karimkhani Aksut C, Wu D, Alicandro G, McGonagle D, et al. The Global, regional, and national burden of psoriasis: results and insights from the Global Burden of Disease 2019 Study. Front Med 2021; 8: 743180.","DOI":"10.3389\/fmed.2021.743180"},{"key":"51392","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fmed.2021.743180","DOI":"10.3389\/fmed.2021.743180"},{"key":"51393","doi-asserted-by":"crossref","unstructured":"Nijsten T, Meads DM, de Korte J, Sampogna F, Gelfand JM, Ongenae K, et al. Cross-cultural inequivalence of dermatology-specific health-related quality of life instruments in psoriasis patients. J Invest Dermatol 2007; 127: 2315-2322.","DOI":"10.1038\/sj.jid.5700875"},{"key":"51394","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/sj.jid.5700875","DOI":"10.1038\/sj.jid.5700875"},{"key":"51395","doi-asserted-by":"crossref","unstructured":"Chicharro P, Llamas-Velasco M, Armesto S, Herrera-Acosta E, Vidal D, Vilarrasa E, et al. Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting. Dermatol Ther 2022; 35: e15653.","DOI":"10.1111\/dth.15653"},{"key":"51396","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.15653","DOI":"10.1111\/dth.15653"},{"key":"51397","doi-asserted-by":"crossref","unstructured":"Ruiz-Villaverde R, Vasquez-Chinchay F, Rodriguez-Fernandez-Freire L, C Armario-Hita J, P\u00e9rez-Gil A, Gal\u00e1n-Guti\u00e9rrez M. Super-responders in moderate-severe psoriasis under guselkumab treatment: myths, realities and future perspectives. Life (Basel) 2022; 12: 1412.","DOI":"10.3390\/life12091412"},{"key":"51398","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/life12091412","DOI":"10.3390\/life12091412"},{"key":"51399","doi-asserted-by":"crossref","unstructured":"Strober B, Papp KA, Lebwohl M, Reich K, Paul C, Blauvelt A, et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol 2016; 75: 77-82.e7.","DOI":"10.1016\/j.jaad.2016.03.026"},{"key":"51400","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2016.03.026","DOI":"10.1016\/j.jaad.2016.03.026"},{"key":"51401","doi-asserted-by":"crossref","unstructured":"Loft ND, Egeberg A, Rasmussen MK, Bryld LE, Gniadecki R, Dam TN, et al. Patient-reported outcomes during treatment in patients with moderate-to-severe psoriasis: a Danish nationwide study. Acta Derm Venereol 2019; 99: 1224-1230.","DOI":"10.2340\/00015555-3331"},{"key":"51402","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-3331","DOI":"10.2340\/00015555-3331"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/20329\/45538","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/20329\/45538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T12:17:41Z","timestamp":1710245861000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/20329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":59,"URL":"https:\/\/doi.org\/10.2340\/actadv.v104.20329","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,12]]}}}